Key Points
-
CHK2 is a versatile and multifunctional kinase that regulates the cell's response to DNA damage by phosphorylating a number of distinct cellular substrates.
-
CHK2 can prevent tumour progression by averting genomic instability through DNA repair and, if this is not possible, by causing the cell to senesce or die.
-
Human genetic studies clearly show that CHEK2 is a multiorgan tumour susceptibility gene, but current evidence indicates that CHEK2 on its own does not predispose to cancer.
-
A potential therapeutic approach in patients whose tumours harbour CHEK2 mutations may be treatment with inhibitors of other proteins that are involved in DNA-repair pathways, inactivation of which may be lethal in combination with a loss of CHEK2.
-
Looking at the other side of the coin, in cancer patients with a functional CHK2 protein a key issue is defining how this kinase manages to elicit distinct cellular outcomes such as cell survival through DNA repair versus apoptosis or senescence.
Abstract
In the past decade, CHK2 has emerged as an important multifunctional player in the DNA-damage response signalling pathway. Parallel studies of the human CHEK2 gene have also highlighted its role as a candidate multiorgan tumour susceptibility gene rather than a highly penetrant predisposition gene for Li–Fraumeni syndrome. As discussed here, our current understanding of CHK2 function in tumour cells, in both a biological and genetic context, suggests that targeted modulation of the active kinase or exploitation of its loss in tumours could prove to be effective anti-cancer strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870 (2005).
Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913 (2005). These two articles demonstrate that CHK2 participates in an anti-cancer barrier in the earliest stages of tumour development.
Sodha, N. et al. Screening hCHK2 for mutations. Science 289, 359 (2000).
Nevanlinna, H. & Bartek, J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25, 5912–5919 (2006).
Cybulski, C. et al. A large germline deletion in CHEK2 is associated with an increased risk of prostate cancer. J. Med. Genet. (2006).
Cybulski, C. et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res. 64, 2677–2679 (2004).
Walsh, T. et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295, 1379–1388 (2006).
Sodha, N. et al. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum. Mutat. 20, 460–462 (2002).
Zhou, B. B. & Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Rev. Cancer 4, 216–225 (2004).
Lord, C. J., Garrett, M. D., Ashworth, A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. 12, 463–468 (2006).
Zhou, B. B. & Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature 408, 433–439 (2000).
Pommier, Y., Sordet, O., Rao, V. A., Zhang, H. & Kohn, K. W. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr. Pharm. Des. 11, 2855–2872 (2005).
Lee, J. S., Collins, K. M., Brown, A. L., Lee, C. H. & Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404, 201–204 (2000). This report shows that BRCA1 is a substrate of CHK2, therefore indicating a direct role for CHK2 in DNA repair.
Zhang, J. et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol. Cell Biol. 24, 708–718 (2004).
Wang, H. C., Chou, W. C., Shieh, S. Y. & Shen, C. Y. Ataxia telangiectasia mutated and checkpoint kinase 2 regulate BRCA1 to promote the fidelity of DNA end-joining. Cancer Res. 66, 1391–1400 (2006).
Zhuang, J. et al. Checkpoint kinase 2-mediated phosphorylation of BRCA1 regulates the fidelity of nonhomologous end-joining. Cancer Res. 66, 1401–1408 (2006).
Tan, Y., Raychaudhuri, P. & Costa, R. H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell Biol. 27, 1007–1016 (2007).
Blasina, A. et al. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 1, 1–10 (1999).
Chaturvedi, P. et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18, 4047–4054 (1999).
Matsuoka, S., Huang, M. & Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893–1897 (1998).
Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM–Chk2–Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842–847 (2001). This report establishes CHK2 as a checkpoint that prevents radioresistant DNA synthesis.
Sorensen, C. S., et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3, 247–258 (2003).
Takai, H. et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21, 5195–5205 (2002).
Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677–1679 (1998).
Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674–1677 (1998).
Shieh, S. Y., Ahn, J., Tamai, K., Taya, Y. & Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14, 289–300 (2000).
Chehab, N. H., Malikzay, A., Appel, M. & Halazonetis, T. D. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev. 14, 278–288 (2000).
Bruno, T. et al. Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. Cancer Cell 10, 473–486 (2006).
Dornan, D., Shimizu, H., Perkins, N. D. & Hupp, T. R. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 278, 13431–13441 (2003).
Ou, Y. H., Chung, P. H., Sun, T. P. & Shieh, S. Y. p53 C-terminal phosphorylation by CHK1 and CHK2 participates in the regulation of DNA-damage-induced C-terminal acetylation. Mol. Biol. Cell 4, 1684–1695 (2005).
Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S. & Chen, J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO 24, 3411–3422 (2005).
LeBron, C., Chen, L., Gilkes, D. M. & Chen, J. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 25, 1196–1206 (2006).
Hirao, A. et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287, 1824–1827 (2000).
Hirao, A. et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell Biol. 18, 6521–6532 (2002).
Jack, M. T., et al. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc. Natl Acad. Sci. USA. 99, 9825–9829 (2002).
Jack, M. T., Woo, R. A., Motoyama, N., Takai, H. & Lee, P. W. DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage. J. Biol. Chem. 279, 15269–15273 (2004).
Li, J. & Stern, D. F. Regulation of CHK2 by DNA-dependent protein kinase. J. Biol. Chem. 280, 12041–12050 (2005).
Yu, Q., Rose, J. H., Zhang, H. & Pommier, Y. Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. FEBS Lett. 505, 7–12 (2001).
Stevens, C., Smith, L. & La Thangue, N. B. Chk2 activates E2F-1 in response to DNA damage. Nature Cell Biol. 5, 401–409 (2003). This report shows that E2F1 is directly phosphorylated by CHK2 in response to DNA damage.
Rogoff, H. A. et al. Apoptosis associated with deregulated E2F activity is dependent on E2F1 and Atm/Nbs1/Chk2. Mol. Cell Biol. 27, 2968–2977 (2004).
Powers, J. T. et al. E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol. Cancer Res. 4, 203–214 (2004).
Yang, S., Kuo, C., Bisi, J. E. & Kim, M. K. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nature Cell Biol. 4, 865–870 (2002).
Yang, S. et al. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation. J. Biol. Chem. 281, 26645–26654 (2006).
Tsvetkov, L., Xu, X., Li, J. & Stern, D. F. Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody. J. Biol. Chem. 278, 8468–8475 (2003).
Bahassi el, M., et al. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 43, 6633–6640 (2002).
Castedo, M. et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23, 4353–4361 (2004).
Ghosh, J. C., Dohi, T., Raskett, C. M., Kowalik, T. F. & Altieri, D. C. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res. 66, 11576–11579 (2006).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Gire, V. et al. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J. 23, 2554–2563 (2004).
Chen, C. R. et al. Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res. 65, 6017–6021 (2005).
Aliouat-Denis, C. M. et al. p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol. Cancer Res. 3, 7–64 (2005).
Di Micco, R., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638–642 (2006).
Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528–2531 (1999). This was the first indication that mutations in CHEK2 wereassociated with cancer.
Li, F. P. et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 48, 5358–5362 (1988).
Birch, J. M. Li-Fraumeni syndrome. Eur. J. Cancer 30, 1935–1941 (1994).
Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
Varley, J. M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21, 313–320 (2003).
Le Bihan, C., Moutou, C., Brugieres, L., Feunteun, J. & Bonaiti-Pellie, C. ARCAD: a method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet. Epidemiol. 12, 13–25 (1995).
Knudson, A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820–823 (1971).
Varley, J. M. et al. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene 14, 865–871 (1997).
Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet. 31, 55–59 (2002). This was the first report to show that CHEK2 1100delC is a low-penetrance cancer susceptibility gene.
Vahteristo, P. et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71, 432–438 (2002).
Oldenburg, R. A. et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res. 63, 8153–8157 (2003).
Seppala, E. H. et al. CHEK2 variants associate with hereditary prostate cancer. Br. J. Cancer 89, 1966–1970 (2003).
Cybulski, C. et al. CHEK2-positive breast cancers in young Polish women. Clin. Cancer Res. 12, 4832–4835 (2006).
Gorski, B. et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res. Treat. 92, 19–24 (2005).
Kilpivaara, O. et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int. J. Cancer 111, 543–547 (2004).
Cybulski, C. et al. CHEK2 is a multiorgan cancer susceptibility gene. Am. J. Hum. Genet. 75, 1131–1135 (2004). This article showed that CHEK2 is a multiorgan cancer susceptibility gene.
Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. Int. J. Cancer 116, 263–266 (2005).
Szymanska-Pasternak, J. et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol. Oncol. 102, 429–431 (2006).
Kilpivaara, O., Alhopuro, P., Vahteristo, P., Aaltonen, L. A. & Nevanlinna, H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J. Med. Genet. 43, e34 (2006).
Rudd, M. F., Sellick, G. S., Webb, E. L., Catovsky, D. & Houlston, R. S. Variants in the ATM–BRCA2–CHEK2 axis predispose to chronic lymphocytic leukemia. Blood 108, 638–644 (2006).
Zlowocka, E. et al. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int. J. Cancer 4 Oct 2007 (doi:10.1002/ijc.23099).
Friedrichsen, D. M., Malone, K. E., Doody, D. R., Daling, J. R. & Ostrander, E. A. Frequency of CHEK2 mutations in a population based, case-control study of breast. 6, R629–R635 (2004).
The CHEK2 Breast Cancer Consortium. A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet. 74, 1175–1182 (2004).
Broeks, A. et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res. Treat. 83, 91–93 (2004).
de Bock, G. H. et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J. Med. Genet. 41, 731–735 (2004).
Kilpivaara, O. et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int. J. Cancer 113, 575–580 (2005).
Schmidt, M. K. et al. Breast cancer survival and tumour characteristic in premenopausal women carrying the CHEK2 1100delC germline mutation. J. Clin. Oncol. 25, 64–69 (2007).
Bernstein, J. L. et al. The CHEK2*1100delC allelic variant and risk of breast cancer screening results from the Breast Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 15, 348–352 (2006).
Cybulski, C. et al. Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. Cancer Epidemiol. Biomarkers Prev. 16, 572–576 (2007).
Shaag, A. et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum. Mol. Genet. 14, 555–563 (2005).
Dong, X. et al. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 72, 270–280 (2003). This is the first report to show that mutations in CHEK2 are associated with prostate cancer.
Cybulski et al. A deletion in CHEK2 of 5395bp predisposes to breast cancer in Poland. Breast Cancer Res. Treat. 102, 119–122 (2007).
Lee, S. B. et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 61, 8062–8067 (2001).
Sodha, N. et al. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br. J. Cancer 87, 1445–1448 (2002).
Schutte, M. et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am. J. Hum. Genet. 72, 1023–1028 (2003).
Dufault, M. R. et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int. J. Cancer 110, 320–325 (2004).
Wu, X., Webster, S. R. & Chen, J. Characterization of tumor-associated Chk2 mutations. J. Biol. Chem. 276, 2971–2974 (2001).
Sodha, N., Mantoni, T. S., Tavtigian, S. V., Eeles, R. & Garrett, M. D. Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res. 66, 8966–8970 (2006).
Wu, X., Dong, X., Liu, W. & Chen, J. Characterization of CHEK2 mutations in prostate cancer. Hum. Mutat. 27, 742–747 (2006).
Jekimovs, C. R. et al. Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals. Br. J. Cancer 92, 784–790 (2005).
van Puijenbroek, M. et al. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype. J. Pathol. 206, 198–204 (2005).
Sullivan, A. et al. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21, 1316–1324 (2002).
Bartkova, J. et al. Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer. Oncogene 23, 8545–8551 (2004).
Koppert, L. B., Schutte, M., Abbou, M., Tilanus, H. W. & Dinjens, W. N. The CHEK2*1100delC mutation has no major contribution in oesophageal carcinogenesis. Br. J. Cancer 90, 888–891 (2004).
Aktas, D., Arno, M. J., Rassool, F. & Mufti, G. J. Analysis of CHK2 in patients with myelodysplastic syndromes. Leuk. Res. 26, 985–987 (2002).
Reddy, A. et al. Analysis of CHK2 in vulval neoplasia. Br. J. Cancer 86, 756–760 (2002).
Hangaishi, A. et al. Mutations of Chk2 in primary hematopoietic neoplasms. Blood 99, 3075–3077 (2002).
Haruki, N. et al. Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res. 60, 4689–4692 (2000).
Ingvarsson, S. et al. Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res. 4, R4 (2002).
Sallinen, S. L., Ikonen, T., Haapasalo, H. & Schleutker, J. CHEK2 mutations in primary glioblastomas. J. Neurooncol. 74, 93–95 (2005).
Miller, C. W. et al. Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer 33, 17–21 (2002).
Williams, L. H., Choong, D., Johnson, S. A. & Campbell, I. G. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin. Cancer Res. 12, 6967–6972 (2006).
Staalesen, V. et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23, 8535–8544 (2004).
Tort, F. et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100, 4602–4608 (2002).
Honrado, E. et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J. Clin. Oncol. 23, 7503–7511 (2005).
Brennan, P. et al. Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum. Mol. Genet. 15, 1794–1801 (2007).
McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).
Morgan, M. A., Parsels, L. A., Parsels, J. D., Lawrence, T. S. & Maybaum, J. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. Cell Cycle 5, 1983–1988 (2006).
Xiao, Z., Xue, J., Sowin, T. J. & Zhang, H. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy. Mol. Cancer Ther. 5, 1935–1943 (2006).
Kohn, E. A., Yoo, C. J. & Eastman, A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 63, 31–35 (2003).
Matthews, D. J. et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle. 6, 104–110 (2007).
Oliver, A. W. et al. Trans-activation of the DNA-damage signalling protein kinase Chk2 by T-loop exchange. EMBO J. 25, 3179–3190 (2006). This paper describes the binding of ATP-competitive small-molecule inhibitors to CHK2 as shown by X-ray crystal structure analyses, and shows CHK2 activation through trans -autophosphorylation.
Jobson, A. G. et al. Identification of a bis-guanylhydrazone (4,4′-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555) as a novel chemotype for inhibition of Chk2 kinase. Mol. Pharmacol. 72, 876–884 (2007).
Larson, G. et al. Identification of novel, selective and potent Chk2 inhibitors. Bioorg. Med. Chem. Lett. 17, 172–175 (2007).
Carlessi, L. et al. Biochemical and cellular characterisation of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol. Cancer Ther. 6, 935–944 (2007). A detailed report on the molecular pharmacological characterization of a selective small-molecule inhibitor of CHK2.
Arienti, K. L. et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 48, 1873–1885 (2005). First report of the discovery and optimization of potent, selective small-molecule CHK2 inhibitors showing radioprotection towards human T cells isolated from blood.
Sturgeon, C. M., Knight, Z. A., Shokat, K. M. & Roberge, M. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol. Cancer Ther. 5, 885–892 (2006). Illustrates and emphasizes the interactions between DNA-damaging events, the DNA-damage response pathway and the DNA repair machinery in cells.
Allen, J. B., Zhou, Z., Siede, W., Friedberg, E. C. & Elledge, S. J. The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev. 8, 2401–2415 (1994).
Murakami, H. & Okayama, H. A kinase from fission yeast responsible for blocking mitosis in S phase. Nature 374, 817–819 (1995).
Matsuoka, S., Huang, M. & Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893–1897 (1998).
Blasina, A. et al. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 9, 1–10 (1999).
Chaturvedi, P. et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18, 4047–4054 (1999).
Brown, A. L. et al. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. Proc. Natl Acad. Sci. USA. 96, 3745–3750 (1999).
Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl Acad. Sci. USA. 97, 10389–10394 (2000).
Hirao, A. et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287, 1824–1827 (2000).
Jack, M. T. et al. Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc. Natl Acad. Sci. USA 99, 9825–9829 (2002).
Hirao, A. et al. Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol. Cell Biol. 22, 6521–6532 (2002).
Jallepalli, P. V., Lengauer, C., Vogelstein, B. & Bunz, F. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J. Biol. Chem. 278, 20475–10479 (2003).
Ahn, J., Urist, M. & Prives, C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. J. Biol. Chem. 278, 20480–20489 (2003).
Ahn, J. Y., Schwarz, J. K., Piwnica-Worms, H. & Canman, C. E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60, 5934–5936 (2000).
Melchionna, R., Chen, X. B., Blasina, A. & McGowan, C. H. Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1. Nature Cell Biol. 2, 762–765 (2000).
Wang, X. Q., Redpath, J. L., Fan, S. T. & Stanbridge, E. J. ATR dependent activation of Chk2. J. Cell Physiol. 208, 613–619 (2006).
Bahassi el, M., Myer, D. L., McKenney, R. J., Hennigan, R. F., Stambrook, P. J. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage. Mutat. Res. 596, 166–176 (2006).
Wei, J. H. et al. TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. J. Biol. Chem. 280, 7748–7757 (2005).
Lee, C. H. & Chung, J. H. The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J. Biol. Chem. 276, 30537–30541 (2001).
Ahn, J. Y., Li, X., Davis, H. L. & Canman, C. E. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J. Biol. Chem. 277, 19389–19395 (2002).
Xu, X., Tsvetkov, L. M. & Stern, D. F. Chk2 activation and phosphorylation-dependent oligomerization. Mol. Cell Biol. 22, 4419–4432 (2002).
Schwarz, J. K., Lovly, C. M. & Piwnica-Worms, H. Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation. Mol. Cancer Res. 1, 598–609 (2003).
Liang, X., Reed, E. & Yu, J. J. Protein phosphatase 2A interacts with Chk2 and regulates phosphorylation at Thr-68 after cisplatin treatment of human ovarian cancer cells. Int. J. Mol. Med. 17, 703–708 (2006).
Fujimoto, H. et al. Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase. Cell Death Differ. 13, 1170–1180 (2006).
Oliva-Trastoy, M. et al. Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene 26, 1449–1458 (2007).
Ahn, J. & Prives, C. Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J. Biol. Chem. 277, 48418–48426 (2002).
Wu, X. & Chen, J. Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis. J. Biol. Chem. 278, 36163–36168 (2003).
Buscemi, G. et al. DNA damage-induced cell cycle regulation and function of novel Chk2 phosphoresidues. Mol. Cell Biol. 26, 7832–7845 (2006).
King, J. B. et al. Accurate mass-driven analysis for the characterization of protein phosphorylation. Study of the human Chk2 protein kinase. Anal. Chem. 78, 2171–2181 (2006).
Kass, E. M. et al. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. J. Biol. Chem. 41, 30311–30321 (2007).
Sharma, V., Tepe, J. J. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg. Med. Chem. Lett. 14, 4319–4321 (2004).
Li, J. et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol. Cell. 5, 1045–1054 (2002).
Falck, J. et al. Functional impact of concomitant versus alternative defects in the Chk2–p53 tumour suppressor pathway. Oncogene 39, 5503–5510 (2001).
Acknowledgements
We would like to apologise to all those researchers whose studies have not been cited because of space limitations. We would like to thank A. Oliver and L. Pearl for providing Fig 2b.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Ian Collins' laboratories have received funding from Astex Therapeutics Ltd and Vernalis Ltd and have participated in collaborative research with Sareum Ltd and Cancer Research Technologies Ltd. Michelle D. Garrett's laboratories have received funding from Astex Therapeutics and have participated in collaborative research with Sarum Ltd and Cancer Research Technologies.
Related links
Glossary
- Cell-cycle checkpoint
-
A molecular check in the cell cycle to prevent initiation of the next phase in case the DNA is damaged or another condition endangers accurate and safe cell division.
- Li–Fraumeni Syndrome
-
(LFS). A rare syndrome characterized by a familial cluster of very early onset cancers at multiple sites, including sarcoma, breast, brain and adrenocortical tumours. Definition of a classical LFS family: a sarcoma at <45 years, one first-degree relative with cancer at <45 years and one first- or second-degree relative in the same lineage with cancer at <45 years.
- Non-homologous end joining repair
-
(NHEJ). Unlike homologous recombination repair, NHEJ rejoins broken ends of DNA following double-strand breaks without using a homologous DNA template and can therefore be accompanied by loss of nucleotides and errors.
- Base-excision repair
-
(BER). BER replaces non-bulky damage of single bases that have been altered by alkylation, oxidation or deamination.
- 14-3-3
-
A group of proteins that bind to phospho-proteins and regulate their action mainly by controlling their subcellular localization.
- Therapeutic index
-
Comparison of the amount of a therapeutic agent that has the desired effect with the amount that causes toxic or side effects.
- E2F
-
Family of transcription factors that regulate the expression of genes implicated in cell-cycle progression and apoptosis, and whose activity is repressed by the retinoblastoma (pRb) tumour suppressor.
- Mitotic catastrophe
-
Another form of cell death that occurs during or just after mitosis and is characterized by micronuclei or multi-nuclei.
- Penetrance
-
The likelihood a given gene present in the germ line of an organism will result in disease.
- Loss of heterozygosity
-
Classical tumour-suppressor genes are considered to be recessive. Thus, cells that contain one normal and one mutated form of a tumour-suppressor gene in the germ line are functionally normal. The condition that results in the loss of the remaining normal allele is known as loss of heterozygosity.
- Dominant negative
-
A dominant-negative mutation occurs when the mutated gene product adversely affects the normal, wild-type gene product within the same cell.
- Pseudogene
-
A defective copy of all the sequence of a functional gene or of portions of it.
- Founder mutation
-
A founder mutation is a mutation in the germline DNA of one or more individuals who are founders of a distinct population.
- First-degree relative
-
A first-degree relative is one of the following: a parent, a sibling or a child.
Rights and permissions
About this article
Cite this article
Antoni, L., Sodha, N., Collins, I. et al. CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?. Nat Rev Cancer 7, 925–936 (2007). https://doi.org/10.1038/nrc2251
Issue Date:
DOI: https://doi.org/10.1038/nrc2251
This article is cited by
-
Association of CHEK2 I157T and SULT1A1 R213H genetic variants with risk of sporadic colorectal cancer in a sample of Egyptian patients
Egyptian Journal of Medical Human Genetics (2022)
-
A Novel CHEK2 Variant Identified by Next-Generation Sequencing in an Italian Family with Li-Fraumeni Syndrome: Case Report
SN Comprehensive Clinical Medicine (2022)
-
The Chk2-PKM2 axis promotes metabolic control of vasculogenic mimicry formation in p53-mutated triple-negative breast cancer
Oncogene (2021)
-
The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review
Cancer Cell International (2020)
-
Kinesin light chain 4 as a new target for lung cancer chemoresistance via targeted inhibition of checkpoint kinases in the DNA repair network
Cell Death & Disease (2020)